Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 1,101–1,200 of 4,275
The Tumor Microenvironment—A Metabolic Obstacle to NK Cells’ Activity
Domagała, J., Lachota, M., Kłopotowska, M., Graczyk‐Jarzynka, A., Domagała, A., Zhylko, A., Soroczyńska, K., & Winiarska, M. (2020) · Cancers · doi:10.3390/cancers12123542 · Cited by 73
Rai, P. (2010) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2010.07.010 · Cited by 73
“eral senescence-associated secretory phenotype (SASP) has been described, also largely dependent on IL-6 and IL-8, that develops upon DNA damage inflicted by radiation or chemotherapeutic drugs and is intensified by oncogenic Ras expression [133].”
BackgroundFang, C., Liu, B., & Wan, M. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01100-4 · Cited by 77
p53’s Extended Reach: The Mutant p53 Secretome
Pavlakis, E., & Stiewe, T. (2020) · Biomolecules · doi:10.3390/biom10020307 · Cited by 68
“As the senescent phenotype is transferred from critically stressed cells via SASP to adjacent tumor cells [71], the resulting increase in their stemness may drive tumor progression to a more aggressive and drug-resistant state [79].”
BackgroundInfluentialKim, D. E., Dollé, M. E. T., Vermeij, W. P., Gyenis, A., Vogel, K., Hoeijmakers, J. H. J., Wiley, C. D., Davalos, A. R., Hasty, P., Desprez, P., et al. (2020) · Aging Cell · doi:10.1111/acel.13072 · Cited by 64
“Senescent cells can alter the tissue microenvironment by secreting SASP factors, which can also create a proinflammatory milieu.”
BackgroundResultInfluentialSelf-citationGinsenoside F1 suppresses astrocytic senescence-associated secretory phenotype
Hou, J., Cui, C.-H., Kim, S., Sung, C. K., & Choi, C. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.02.002 · Cited by 69
Cellular Senescence in Idiopathic Pulmonary Fibrosis
Kellogg, D. L., Kellogg, D. L., Musi, N., & Nambiar, A. M. (2021) · Current Molecular Biology Reports · doi:10.1007/s40610-021-00145-4 · Cited by 67
The senescent hepatocyte gene signature in chronic liver disease
Aravinthan, A., Shannon, N., Heaney, J., Hoare, M., Marshall, A., & Alexander, G. J. M. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.09.011 · Cited by 65
Emerging roles of lnc RNA s in senescence
Montes, M., & Lund, A. H. (2016) · FEBS Journal · doi:10.1111/febs.13679 · Cited by 69
Microglia: Friend and foe in tauopathy
Odfalk, K. F., Bieniek, K. F., & Hopp, S. C. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102306 · Cited by 60
Pink1 and Parkin regulateDrosophilaintestinal stem cell proliferation during stress and aging
Koehler, C. L., Perkins, G. A., Ellisman, M. H., & Jones, D. L. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201610036 · Cited by 70
“Cellular senescence is a potent tumor-suppressive mechanism, yet numerous recent studies have indicated that the presence of senescent cells can contribute to age-related tissue degeneration through the induction of a senescence-associated secretory phenotype (Coppé et al., 2008) and elevated levels of ROS (Passos et…”
BackgroundMavrogonatou, E., Papadopoulou, A., Pratsinis, H., & Kletsas, D. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00178.2023 · Cited by 66
p53 in senescence – it's a marathon, not a sprint
Sheekey, E., & Narita, M. (2021) · FEBS Journal · doi:10.1111/febs.16325 · Cited by 66
Medina, R. J., O'Neill, C. L., O'Doherty, T. M., Chambers, S. E. J., Guduric-Fuchs, J., Neisen, J., Waugh, D. J., Simpson, D. A., & Stitt, A. W. (2013) · Stem Cells · doi:10.1002/stem.1414 · Cited by 64
Regulation of senescence escape by the cdk4–EZH2–AP2M1 pathway in response to chemotherapy
Le Duff, M., Gouju, J., Jonchère, B., Guillon, J., Toutain, B., Boissard, A., Henry, C., Guette, C., Lelièvre, E., & Coqueret, O. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0209-y · Cited by 64
Cormenier, J., Martin, N., Deslé, J., Salazar-Cardozo, C., Pourtier, A., Abbadie, C., & Pluquet, O. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.003 · Cited by 64
The emerging role of cellular senescence in renal diseases
Zhou, B., Wan, Y., Chen, R., Zhang, C., Li, X., Meng, F., Glaser, S., Wu, N., Zhou, T., Li, S., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14952 · Cited by 64
Senescence: A DNA damage response and its role in aging and Neurodegenerative Diseases
Shreeya, T., Ansari, M. S., Kumar, P., Saifi, M., Shati, A. A., Alfaifi, M. Y., & Elbehairi, S. E. I. (2024) · Frontiers in Aging · doi:10.3389/fragi.2023.1292053 · Cited by 83
Ren, J., Stroncek, D. F., Zhao, Y., Jin, P., Castiello, L., Civini, S., Wang, H., Feng, J., Tran, K., Kuznetsov, S. A., et al. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.07.005 · Cited by 66
“…growth factors and cytokines in the BMSC culture supernatant, which revealed results consistent with a previously described senescence-associated secretory phenotype, including rising levels of IL-6, IL-8, ICAM-1 and TNFRSF11B (Coppe et al., 2008; Lafferty-Whyte et al.; Wang and Jang, 2009).”
BackgroundResultInfluentialCell Senescence, Multiple Organelle Dysfunction and Atherosclerosis
Machado-Oliveira, G., Ramos, C., Marques, A. R. A., & Vieira, O. V. (2020) · Cells · doi:10.3390/cells9102146 · Cited by 80
“In addition, it has been reported that all senescent cells share a common secretory profile and that each particular senescent cell type also tends to express more specific secretory factors (see Table 1 to compare differential secretome profiles between cell types) [48].”
BackgroundWallis, R., Milligan, D., Hughes, B., Mizen, H., López-Domínguez, J. A., Eduputa, U., Tyler, E. J., Serrano, M., & Bishop, C. L. (2022) · Aging · doi:10.18632/aging.204072 · Cited by 58
Placental aging and oxidation damage in a tissue micro-array model: an immunohistochemistry study
Londero, A. P., Orsaria, M., Marzinotto, S., Grassi, T., Fruscalzo, A., Calcagno, A., Bertozzi, S., Nardini, N., Stella, E., Lellé, R. J., et al. (2016) · Histochemistry and Cell Biology · doi:10.1007/s00418-016-1435-6 · Cited by 64
“* Ambrogio P. Londero ambrogio.londero@gmail.com 1 Clinic of Obstetrics and Gynecology, Deparment of Experimental Clinical and Medical Science, University of Udine, Piazzale SM della Misericordia, 15, 33100 Udine, Italy 2 Unit of Obstetrics and Gynecology, S. Polo Hospital, 34074 Monfalcone, GO, Italy 3 Department of…”
InfluentialSenescent stromal cells: roles in the tumor microenvironment
Gabai, Y., Assouline, B., & Ben‐Porath, I. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.09.002 · Cited by 68
Burton, D. G. A., Giribaldi, M. G., Muñoz, A., Halvorsen, K. T., Patel, A., Jordà, M., Perez‐Stable, C., & Rai, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068003 · Cited by 73
Wang, H., Yuan, S., Zheng, Q., Zhang, S., Zhang, Q., Ji, S., Wang, W. J., Cao, Y., Guo, Y., Yang, X., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.025 · Cited by 69
Gao, B., Lin, X., Jing, H., Fan, J., Ji, C., Jie, Q., Zheng, C., Wang, D., Xu, X., Hu, Y., et al. (2018) · Aging Cell · doi:10.1111/acel.12741 · Cited by 63
“…by local delivery of tetramethylpyrazine attenuates bone loss and improves the metabolic microenvironment in aging mice During aging, senescent cells accumulate in various tissues and organs (Campisi, 2005) and disrupt tissue structure and function (Coppe et al., 2008; Rodier & Campisi, 2011).”
BackgroundMas‐Bargues, C., Sanz‐Ros, J., Román-Domínguez, A., Gimeno-Mallench, L., Inglés, M., Viña, J., & Borrás, C. (2020) · Biomolecules · doi:10.3390/biom10060957 · Cited by 73
“SASP is characterized by the secretion of myriad factors, as well as the release of small extracellular vesicles, including exosomes and microvesicles [17,18].”
BackgroundAndrogen Receptor Drives Cellular Senescence
Mirochnik, Y., Veliceasa, D., Williams, L. V., Maxwell, K. M., Yemelyanov, A. Y., Budunova, I. V., & Volpert, O. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031052 · Cited by 71
Innate immunosensing of DNA in cellular senescence
Glück, S., & Ablasser, A. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.09.013 · Cited by 66
Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis
Walton, C. C., Begelman, D., Nguyen, W., & Andersen, J. K. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00129 · Cited by 62
Telomere shortening produces an inflammatory environment that increases tumor incidence in zebrafish
Lex, K., Maia-Gil, M., Lopes-Bastos, B., Figueira, M., Marzullo, M., Giannetti, K., Carvalho, T., & Ferreira, M. G. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920049117 · Cited by 62
“These data constitute a strong indication that cells with Lex et al. PNAS | June 30, 2020 | vol. 117 | no. 26 | 15071 CE LL BI O LO G Y short telomeres are a source of paracrine SASP in vivo.”
BackgroundInfluentialSenescence in chronic wounds and potential targeted therapies
Wei, X., Li, M., Zheng, Z., Ma, J., Gao, Y., Chen, L., Peng, Y., Yu, S., & Yang, L. (2021) · Burns & Trauma · doi:10.1093/burnst/tkab045 · Cited by 72
“This phenotype, termed the ‘senescence-associated secretory phenotype’ (SASP), is an essential feature in distinguishing senescent cells from nonsenescent, quiescent and terminally differentiated cells [46].”
BackgroundControlled DNA double-strand break induction in mice reveals post-damage transcriptome stability
Kim, J., Sturgill, D., Tran, A. D., Sinclair, D. A., & Oberdoerffer, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1482 · Cited by 62
“…of note that epigenetic dysfunction in a small subset of cells may be sufficient to affect entire tissues, and possibly organismal aging, as evidenced by the systemic impact of aberrantly expressed inflammatory cytokines derived from senescent cells (senescence-associated secretory phenotype) (20).”
Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence
Wang, D., Xiao, F., Feng, Z., Li, M., Kong, L., Huang, L., Wei, Y., Li, H., Liu, F., Zhang, H., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01346-y · Cited by 74
“kines, chemokines, and growth factors [19].”
Alessio, N., Aprile, D., Squillaro, T., Bernardo, G. D., Finicelli, M., Melone, M. A. B., Peluso, G., & Galderisi, U. (2019) · Aging · doi:10.18632/aging.102172 · Cited by 69
“Some investigations showed that the SASP released by senescent fibroblasts may promote cancer [5-10].”
BackgroundKsiążek, K., Mikuła‐Pietrasik, J., Catar, R. A., Dworacki, G., Winckiewicz, M., Frydrychowicz, M., Dragun, D., Staniszewski, R., Jörres, A., & Witowski, J. (2009) · International Journal of Cancer · doi:10.1002/ijc.25036 · Cited by 67
COPD-derived fibroblasts secrete higher levels of senescence-associated secretory phenotype proteins
Woldhuis, R. R., Heijink, I. H., van den Berge, M., Timens, W., Oliver, B. G. G., de Vries, M., & Brandsma, C.-A. (2021) · Thorax · doi:10.1136/thoraxjnl-2020-215114 · Cited by 62
Xue, H., Zhao, B., Zhou, W., Liu, H., Fukumoto, T., Gabrilovich, D. I., & Zhang, R. (2020) · iScience · doi:10.1016/j.isci.2020.102016 · Cited by 65
“Senescent cells also have non-cell autonomous activities exemplified by secretion of inflammatory cytokines and chemokines, which is termed the senescence-associated secretory phenotype (SASP) (Coppe et al., 2008).”
BackgroundAirway and serum biochemical correlates of refractory neutrophilic asthma
Alam, R., Good, J. T., Rollins, D. R., Verma, M., Chu, H., Pham, T., & Martin, R. J. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.12.963 · Cited by 63
Azad, A., Jackson, S., Cullinane, C. M., Natoli, A. L., Neilsen, P. M., Callen, D. F., Maira, S.-M., Hackl, W., McArthur, G. A., & Solomon, B. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0312 · Cited by 62
“While transient DNA damage signaling results in a reversible cell-cycle arrest, Rodier and colleagues recently showed that irreversible growth arrest and the acquisition of a SASP are dependent upon persistent activation of the DDR (43).”
BackgroundInfluentialAge-Related Changes in the Cellular Composition and Epithelial Organization of the Mouse Trachea
Wansleeben, C., Bowie, E., Hotten, D. F., Yu, Y.-R. A., & Hogan, B. L. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093496 · Cited by 62
Vascular senescence and aging: mechanisms, clinical implications, and therapeutic prospects
Picos, A., Seoane, N., Campos‐Toimil, M., & Viña, D. (2025) · Biogerontology · doi:10.1007/s10522-025-10256-5 · Cited by 91
“Furthermore, senescent cells actively secrete pro-inflammatory cytokines, growth factors, and proteases, collectively constituting the senescence-associated secretory phenotype (SASP) (Acosta et al. 2013; Coppé et al. 2008).”
Abdelgawad, I. Y., Agostinucci, K. J., Sadaf, B., Grant, M. K. O., & Zordoky, B. N. M. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1170434 · Cited by 76
“One characteristic feature of senescent cells is the secretion of SASP, which consists of multiple components including pro-inflammatory cytokines, chemokines, and proteases (Coppe et al., 2008).”
BackgroundTomari, H., Kawamura, T., Asanoma, K., Egashira, K., Kawamura, K., 本庄, 考., Nagata, Y., & Kato, K. (2020) · Biology of Reproduction · doi:10.1093/biolre/ioaa044 · Cited by 72
“Although cell cycle arrest is a hallmark of senescent cells, recent research has revealed that they secrete a variety of physiologically active molecules such as inflammatory cytokines, chemokines, growth factors, and matrix metalloproteinases [25, 26].”
DNA Damage: From Chronic Inflammation to Age-Related Deterioration
Ιωαννίδου, Ά., Goulielmaki, E., & Garinis, G. A. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00187 · Cited by 68
Breast cancer genomes — form and function
Korkola, J. E., & Gray, J. W. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.11.005 · Cited by 85
“Key microenvironmental factors that contribute to cancer progression include microenvironmental remodeling via matrix metalloproteinases [45–47], macrophage-mediated metastasis [48], senescence-associated cytokine production [49], changes in tissue architecture [50], estrogen-related stromal–epithelial cell crosstalk…”
BackgroundGuo, H., Liu, Z., Xu, B., Hu, H., Wei, Z., Liu, Q., Zhang, X., Ding, X., Wang, Y., Zhao, M., et al. (2013) · Aging Cell · doi:10.1111/acel.12138 · Cited by 62
“CXCR2 induction and SASP are differentially regulated Senescent cells are known to be capable of producing cytokines, chemokines, and other soluble factors, a phenomenon known as SASP (Coppe et al., 2008; Kuilman & Peeper, 2009).”
BackgroundInfluentialPancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight
Cortesi, M., Zanoni, M., Pirini, F., Tumedei, M. M., Ravaioli, S., Rapposelli, I. G., Frassineti, G. L., & Bravaccini, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010254 · Cited by 65
“Despite the protective role of OIS in PDAC, accumulating evidence has underpinned the role of sustained and prolonged senescence signaling in tumor progression, mainly due to the pro-inflammatory molecules composing the SASP [124,156].”
BackgroundPositive and negative effects of cellular senescence during female reproductive aging and pregnancy
Velarde, M. C., & Menon, R. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0018 · Cited by 61
“In addition, a gradual decrease in telomere length is also thought to promote the senescent phenotype in fetal membranes, as indicated by morphologic (enlargement of organelles) and biochemical alterations (activation of MAPK14, increase in SA-β-gal activity and development of the SASP) (Menon et al.”
BackgroundInfluentialBientinesi, E., Lulli, M., Becatti, M., Ristori, S., Margheri, F., & Monti, D. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111689 · Cited by 61
Effects of GH/IGF on the Aging Mitochondria
Poudel, S. B., Dixit, M., Neginskaya, M. A., Nagaraj, K., Pavlov, E. V., Werner, H., & Yakar, S. (2020) · Cells · doi:10.3390/cells9061384 · Cited by 65
Fatt, M. P., Tran, L. M., Vetere, G., Storer, M. A., Simonetta, J. V., Miller, F. D., Frankland, P. W., & Kaplan, D. R. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.12.010 · Cited by 58
“Second, quantitative PCR (qPCR) showed that three senescence-associated mRNAs, Il6, Adam10, and Adam17 (Coppé et al., 2008; Kuilman et al., 2008), were also increased by camptothecin (Figure 3E) (Il6— control, 1.”
BackgroundInfluentialThadathil, N., Selvarani, R., Mohammed, S., Nicklas, E. H., Tran, A. L., Kamal, M., Luo, W., Brown, J. L., Lawrence, M. M., Borowik, A., et al. (2022) · Aging Cell · doi:10.1111/acel.13676 · Cited by 64
“We also measured the expression of twelve of the senescent associated secretory phenotype (SASP) factors commonly expressed by senescent cells (Acosta et al., 2008; Coppe et al., 2008).”
BackgroundSenescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword
Battram, A. M., Bachiller, M., & Martín-Antonio, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124346 · Cited by 69
Cellular senescence: unravelling complexity
Passos, J. F., Simillion, C., Hallinan, J. S., Wipat, A., & von Zglinicki, T. (2009) · AGE · doi:10.1007/s11357-009-9108-1 · Cited by 71
“Coppe and colleagues have shown that the senescent secretory phenotype takes 7–10 days to develop after induction of a DNA damage response (Coppé et al. 2008).”
BackgroundOxidized extracellular DNA as a stress signal that may modify response to anticancer therapy
Glebova, K. V., Вейко, Н. Н., Kostyuk, S. V., Izhevskaya, V. L., & Baranova, A. V. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.005 · Cited by 61
The Emerging Role of Senescence in Ocular Disease
Sreekumar, P. G., Hinton, D. R., & Kannan, R. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2583601 · Cited by 61
“, replicative senescence, DNA damage-induced senescence, oncogene-induced senescence) [14, 116, 117].”
BackgroundInfluentialSenescence and cancer: An evolving inflammatory paradox
Ruhland, M. K., Coussens, L. M., & Stewart, S. A. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.10.001 · Cited by 60
“Extracellular matrix modifying enzymes, such as the canonical SASP factor matrix metalloproteinase (MMP)-3, disrupts normal tissue structure and drives invasive properties along with factors such as IL-6 and IL-8 (26, 54, 55).”
InfluentialKhalil, R., Diab‐Assaf, M., & Lemaître, J.-M. (2023) · Cells · doi:10.3390/cells12060915 · Cited by 73
“This observation describes only one particular type of cellular senescence that is caused by the attrition of telomeres, called replicative senescence (RS), a naturally occurring process that takes place every cell division [50].”
BackgroundDeng, Y., Chen, Q., Yang, X., Sun, Y., Zhang, B., Wei, W., Deng, S., Meng, J., Hu, Y., Wang, Y., et al. (2024) · Theranostics · doi:10.7150/thno.91119 · Cited by 81
“In addition, senescent cells promote reprogramming of the embryonic state partially through IL-6, which can support tissue regeneration on the one hand and facilitate tumor development on the other [4, 13-15].”
Self-citationGualdi, G., Costantini, E., Reale, M., & Amerio, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095037 · Cited by 70
“Moreover, it has been reported that senescent keratinocytes increase the production of the anti-angiogenic factor maspin (mammary serine protease inhibitor) [99], which may be detrimental to the repair process [100,101].”
BackgroundGremmels, H., Teraa, M., Quax, P. H. A., den Ouden, K., Fledderus, J. O., & Verhaar, M. C. (2014) · Molecular Therapy · doi:10.1038/mt.2014.161 · Cited by 65
Cellular Senescence and Senotherapies in the Kidney: Current Evidence and Future Directions
Docherty, M. H., Baird, D., Hughes, J., & Ferenbach, D. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00755 · Cited by 69
“…cytokines, chemokines, growth factors, and proteases which act in an autocrine and paracrine fashion on neighboring cells and are critical to understanding the impact senescent cells have on the function of tissues and organs (Coppe et al., 2008; Coppe et al., 2010; Laberge et al., 2012).”
BackgroundInfluentialSOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence
Mallette, F. A., Calabrese, V., Ilangumaran, S., & Ferbeyre, G. (2010) · Aging · doi:10.18632/aging.100163 · Cited by 69
“The sum of these secreted factors constitutes what has been named the senescence-associated secretory phenotype (SASP) [50].”
Ring, N. A. R., Valdivieso, K., Grillari, J., Redl, H., & Ogrodnik, M. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.04.005 · Cited by 60
Cellular senescence and protein degradation: Breaking down cancer
Deschênes-Simard, X., Lessard, F., Gaumont-Leclerc, M.-F., Bardeesy, N., & Ferbeyre, G. (2014) · Cell Cycle · doi:10.4161/cc.29335 · Cited by 61
Chen, Y., Wang, Y., Huang, Y., Zeng, H., Hu, B., Guan, L., Zhang, H., Yu, A., Johnson, C. H., Gonzalez, F. J., et al. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx023 · Cited by 69
Targeting Immune Senescence in Atherosclerosis
Vellasamy, D. M., Lee, S.-J., Goh, K. W., Goh, B. H., Tang, Y.-Q., Ming, L. C., & Yap, W. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113059 · Cited by 66
“In the atherosclerotic plaque site, the uPA/uPAR/PAI-1 axis is involved in enhanced monocyte recruitment as well as macrophages and foam cell formation [86].”
BackgroundcGAS/STING signalling pathway in senescence and oncogenesis
Yu, L., & Liu, P. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.08.007 · Cited by 72
Detection of the Senescence-Associated Secretory Phenotype (SASP)
Rodier, F. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_10 · Cited by 60
Self-citationZhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 80
“Increased IL-6 and IL-8 levels can promote the EMT and tumor cell invasion [174].”
BackgroundMolecular pathology endpoints useful for aging studies
Niedernhofer, L. J., Kirkland, J. L., & Ladiges, W. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.012 · Cited by 59
Gayle, S. S., Sahni, J. M., Webb, B. M., Weber-Bonk, K. L., Shively, M. S., Spina, R., Bar, E. E., Summers, M. K., & Keri, R. A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004712 · Cited by 60
“Given the potential for cancer cells to reenter the cell cycle following long-term senescence (21,22) and the ability of senescent cells to secrete oncogenic growth-stimulatory factors (23), it is essential to elucidate the mechanisms by which the senescent/apoptotic choice is made to provide a potential therapeutic p…”
BackgroundBorovski, T., Beke, P., van Tellingen, O., Rodermond, H. M., Verhoeff, J. J. C., Lascano, V., Daalhuisen, J. B., Medema, J. P., & Sprick, M. R. (2012) · Oncogene · doi:10.1038/onc.2012.172 · Cited by 67
The crosstalk of telomere dysfunction and inflammation through cell-free TERRA containing exosomes
Wang, Z., & Lieberman, P. M. (2016) · RNA Biology · doi:10.1080/15476286.2016.1203503 · Cited by 60
“flammatory cytokines, chemokines, growth factors, and proteases.(8) However, the molecular mechanisms driving SASP are”
BackgroundImpact of aging immune system on neurodegeneration and potential immunotherapies
Liang, Z., Zhao, Y., Ruan, L., Zhu, L., Jin, K., Zhuge, Q., Su, D., & Zhao, Y. L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.07.006 · Cited by 67
Extracellular Vesicles in Aging: An Emerging Hallmark?
Manni, G., Buratta, S., Pallotta, M. T., Chiasserini, D., Michele, A. D., Emiliani, C., Giovagnoli, S., Pascucci, L., Romani, R., Bellezza, I., et al. (2023) · Cells · doi:10.3390/cells12040527 · Cited by 70
Death by transposition – the enemy within?
Sedivy, J. M., Kreiling, J. A., Neretti, N., Cecco, M. D., Criscione, S. W., Hofmann, J. W., Zhao, X., Ito, T., & Peterson, A. L. (2013) · BioEssays · doi:10.1002/bies.201300097 · Cited by 60
“Whether the senescence-associated secretory phenotype (SASP [92, 93]) is impacted in any way by RTE mobilization has not been examined.”
BackgroundAge-associated stresses induce an anti-inflammatory senescent phenotype in endothelial cells
Coleman, P. R., Chang, G., Hutas, G., Grimshaw, M., Vadas, M. A., & Gamble, J. R. (2013) · Aging · doi:10.18632/aging.100622 · Cited by 60
“However, these studies have principally been performed in fibroblasts and epithelial cells and it is known that cell type and stimulant specific responses exist in the induction of senescence [40].”
BackgroundMalaquin, N., Vancayseele, A., Gilbert, S., Antenor-Habazac, L., Olivier, M.-A., Ait Ali Brahem, Z., Saad, F., Delouya, G., & Rodier, F. (2020) · Cells · doi:10.3390/cells9071593 · Cited by 59
“Despite these mutations, cancer cells can often retain the capacity to enter senescence in response to treatments [16,20,29,30].”
BackgroundSelf-citationBlokland, K. E. C., Waters, D. W., Schuliga, M., Read, J., Pouwels, S. D., Grainge, C. L., Jaffar, J., Westall, G., Mutsaers, S. E., Prêle, C. M., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040389 · Cited by 57
“To identify potential mechanisms by which senescent cells impact on alveolar epithelial cells modulation of known SASP factors such as IL-6, IL-1β, PDGF, FGFb, PGE2 and ROS would be the focus of future studies [41,42].”
BackgroundModeling radiation-induced lung injury: lessons learned from whole thorax irradiation
Beach, T. A., Groves, A. M., Williams, J. P., & Finkelstein, J. N. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1532619 · Cited by 69
“Similar increases in cytokine expression have also been observed in vitro with X-ray induced senescent epithelial cells; these cells secreted significantly increased levels of IL-6, IL-8, MCP-1, IL-1a, IL-1b, GM-CSF, VEGF, and IGFBP2 compared to unirradiated, pre-senescent controls (Coppe et al. 2008).”
BackgroundInfluentialEpigenetic gene regulation by histone demethylases: emerging role in oncogenesis and inflammation
Kang, M., Mehrazarin, S., Park, N., & Wang, C. (2016) · Oral Diseases · doi:10.1111/odi.12569 · Cited by 68
“…in that senescence triggers secretion of a discrete pattern of inflammatory cytokines, such as interleukin-6 (IL-6), IL-8, and GRO-α, collectively named senescence-associated secretory phenotype (SASP) originally observed in culture models exposed to genotoxic stress (Coppe et al, 2008).”
BackgroundEstablishing mechanisms affecting the individual response to ionizing radiation
Averbeck, D., Candéias, S. M., Chandna, S., Foray, N., Friedl, A. A., Haghdoost, S., Jeggo, P. A., Lumniczky, K., Paris, F., Quintens, R., et al. (2019) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1704908 · Cited by 78
“The initiation and the maintenance of the senescent associated secretory phenotype (SASP) requires the persistence of DNA damage from months to years after IR (Coppe et al. 2008; Rodier et al. 2009; Strzeszewska et al. 2018).”
BackgroundInflammation: A hidden path to breaking the spell of ovarian cancer
Shan, W., & Liu, J. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9590 · Cited by 68
“, ICAM-1, VCAM-1, integrins),(37) suggesting that upon senescence, aged cells take up the highly pro-inflammatory “senescence-associated secretory phenotype” (SASP).(38) Our laboratory has found direct evidence that senescent ovarian fibroblasts promote ovarian epithelial tumorigenesis by mobilizing the pro-inflammato…”
BackgroundA New Gene Set Identifies Senescent Cells and Predicts Senescence-Associated Pathways Across Tissues
(2021) · doi:10.1101/2021.12.10.472095 · Cited by 58
Senescent fibroblast-derived Chemerin promotes squamous cell carcinoma migration
Farsam, V., Basu, A., Gatzka, M., Treiber, N., Schneider, L. A., Mulaw, M. A., Lucas, T., Kochanek, S., Dummer, R., Levesque, M. P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13446 · Cited by 59
Accumulation of DNA damage in the aged hematopoietic stem cell compartment
Beerman, I. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.11.001 · Cited by 57
“These two mechanisms of handling DNA damage are thought to play a major role in tumor suppression, but may also contribute to aging phenotypes through cellular attrition due to apoptosis or tissue dysregulation caused by factors secreted by senescent cells (senescenceassociated secretory phenotype or SASP)(6-8) with b…”
BackgroundInnate Immunity System in Patients With Cardiovascular and Kidney Disease
Zoccali, C., & Mallamaci, F. (2023) · Circulation Research · doi:10.1161/circresaha.122.321749 · Cited by 65
Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells
Bargiela-Iparraguirre, J., Prado-Marchal, L., Pajuelo‐Lozano, N., Jiménez, B., Perona, R., & Sánchez‐Pérez, I. (2014) · Cell Cycle · doi:10.4161/15384101.2014.962952 · Cited by 63
“On the other hand, we can argue that in the absence of Mad2 or BubR1, the PTX treatment leads to a prolonged arrest, probably increasing free radicals, which are crucial for SASP regulation.(46) The secretome of senescent cells is complex, consisting of a range of cytokines, chemokines and proteases, among other subst…”
BackgroundCarbonneau, C. L., Despars, G., Rojas-Sutterlin, S., Fortin, A., Le, O., Hoang, T., & Beauséjour, C. M. (2012) · Blood · doi:10.1182/blood-2011-06-361626 · Cited by 59
Minieri, V., Saviozzi, S., Gambarotta, G., Iacono, M. L., Accomasso, L., Rocchietti, E. C., Gallina, C., Turinetto, V., & Giachino, C. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12387 · Cited by 70
“In fact, senescent cells with persistent DDR signalling show a robust increase in mRNA levels and protein secretion of numerous cytokines, growth factors and proteases [26, 37, 48], some of which, like IL6 and IL8, are involved in the reinforcing of the growth arrest [49, 50] and exert a tumour promoting role [51].”
BackgroundKim, H., Jang, J., Song, M. J., Park, C., Lee, D. H., Lee, S., & Chung, J. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113034 · Cited by 69
New Insights into the Role of Epithelial–Mesenchymal Transition during Aging
Santos, F. D. S., Moreira, C., Pereira, S. N., & de Jesus, B. B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040891 · Cited by 61
“Senescent-associated secretory phenotype derived from senescent fibroblasts has the ability to induce EMT in neighboring epithelial cells and has been shown to contribute to EMT in non-aggressive human breast cancer cell lines [70,71].”
BackgroundInfluentialRetinoic acid inducible gene-I, more than a virus sensor
Liu, F., & Gu, J. (2011) · Protein & Cell · doi:10.1007/s13238-011-1045-y · Cited by 58
“Senescent cells secrete a spectrum of proinflammatory factors and chemokines, such as IL-6 and IL8, which is called senescence associated secretory phenotype (SASP) (Coppé et al., 2008).”
BackgroundMidha, A., Pan, H., Abarca, C., Andle, J., Carapeto, P., Bonner-Weir, S., & Aguayo-Mazzucato, C. (2021) · Diabetes · doi:10.2337/db20-0553 · Cited by 58
JNK in Tumor Microenvironment: Present Findings and Challenges in Clinical Translation
Tam, S. Y., & Law, H. (2021) · Cancers · doi:10.3390/cancers13092196 · Cited by 65
“Ras initiation promotes pro-malignant paracrine mechanism mainly by IL-6 and IL-8 [58].”
BackgroundGoronzy, J. J., Hu, B., Kim, C., Jadhav, R. R., & Weyand, C. M. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ri0418-160r · Cited by 60
The mutant p53 mouse as a pre-clinical model
Jackson, J. G., & Lozano, G. (2013) · Oncogene · doi:10.1038/onc.2012.610 · Cited by 57
Ortiz‐Lazareno, P. C., Bravo‐Cuéllar, A., Lerma-Díaz, J. M., Jave‐Suárez, L. F., Aguilar‐Lemarroy, A., Domínguez-Rodríguez, J. R., González‐Ramella, O., Célis, R. D., Gómez-Lomelí, P., & Hernández‐Flores, G. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-13 · Cited by 60
“Whether cellular senescence induced by antitumor therapy can act as friend or foe is difficult to determine precisely because recent data indicate that factors secreted by senescent cells can also alter the microenvironment and enhance the tumor growth of neighboring tumor cells, indicating that this protective mechan…”
Background
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.